GlassScriptPhysician profile
Michelle C Gooch
NPI 1861408130
$2,884.99
in general payments reported to CMS, 2019-2025
30 companies · $410 in 2025
The $410 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $270 · 2021: $484 · 2022: $474 · 2023: $592 · 2024: $263 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.62 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $450.63 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $389.14 | 2022-2025 | |
| Astellas Pharma US INC | $286.23 | 2019-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $186.80 | 2020-2025 | Slynd |
| Hologic Sales and Service, LLC | $167.82 | 2019-2025 | Aptima |
| Shield Therapeutics INC | $117.83 | 2024-2025 | |
| Therapeuticsmd, INC. | $112.18 | 2019-2022 | |
| Evofem Biosciences, INC. | $108.54 | 2021-2025 | Phexxi, Solosec, Phexx |
| Avion Pharmaceuticals | $106.92 | 2019-2023 | Balcoltra |
| Abbvie INC. | $99.65 | 2019-2022 | |
| Lupin INC. | $92.37 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $89.02 | 2021 | |
| Sumitomo Pharma America, INC. | $88.41 | 2023-2024 | Gemtesa, Myfembree |
| Dysis Medical, INC. | $88.16 | 2021 | |
| Amag Pharmaceuticals, INC. | $68.52 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $67.10 | 2023-2025 | Cologuard Collection Kit |
| Myriad Women'S Health, INC. | $65.23 | 2023 | Myrisk |
| Millicent US INC | $35.63 | 2023 | Intrarosa |
| Agile Therapeutics, INC. | $32.85 | 2021 | |
| Coopersurgical, INC. | $32.40 | 2019-2022 | |
| Allergan, INC. | $31.54 | 2019 | |
| Novo Nordisk INC | $29.26 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $23.15 | 2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $21.97 | 2020 | |
| Currax Pharmaceuticals LLC | $18.00 | 2023 | Contrave, Onzetra Xsail |
| Mission Pharmacal Company | $17.87 | 2021 | |
| Biogen, INC. | $15.74 | 2025 | Zurzuvae |
| Ascend Therapeutics US, LLC | $15.46 | 2023 | |
| Duchesnay USA Incorporated | $14.91 | 2019 | |
| Medtronic, INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Gooch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.